128 related articles for article (PubMed ID: 25418156)
1. Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.
Vieira Neto L; Wildemberg LE; Moraes AB; Colli LM; Kasuki L; Marques NV; Gasparetto EL; de Castro M; Takiya CM; Gadelha MR
Clin Endocrinol (Oxf); 2015 May; 82(5):739-46. PubMed ID: 25418156
[TBL] [Abstract][Full Text] [Related]
2. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment.
Pivonello R; Matrone C; Filippella M; Cavallo LM; Di Somma C; Cappabianca P; Colao A; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1674-83. PubMed ID: 15070930
[TBL] [Abstract][Full Text] [Related]
3. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
Greenman Y; Cooper O; Yaish I; Robenshtok E; Sagiv N; Jonas-Kimchi T; Yuan X; Gertych A; Shimon I; Ram Z; Melmed S; Stern N
Eur J Endocrinol; 2016 Jul; 175(1):63-72. PubMed ID: 27150495
[TBL] [Abstract][Full Text] [Related]
4. Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.
Lohmann T; Trantakis C; Biesold M; Prothmann S; Guenzel S; Schober R; Paschke R
Pituitary; 2001 Aug; 4(3):173-8. PubMed ID: 12138990
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptor expression and function in corticotroph pituitary tumors.
Pivonello R; Ferone D; de Herder WW; Kros JM; De Caro ML; Arvigo M; Annunziato L; Lombardi G; Colao A; Hofland LJ; Lamberts SW
J Clin Endocrinol Metab; 2004 May; 89(5):2452-62. PubMed ID: 15126577
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial.
Batista RL; Musolino NRC; Cescato VAS; da Silva GO; Medeiros RSS; Herkenhoff CGB; Trarbach EB; Cunha-Neto MB
Am J Clin Oncol; 2019 Feb; 42(2):221-227. PubMed ID: 30540568
[TBL] [Abstract][Full Text] [Related]
7. ACTH silent adenoma shrinking under cabergoline.
Petrossians P; Ronci N; Valdés Socin H; Kalife A; Stevenaert A; Bloch B; Tabarin A; Beckers A
Eur J Endocrinol; 2001 Jan; 144(1):51-7. PubMed ID: 11174837
[TBL] [Abstract][Full Text] [Related]
8. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
[TBL] [Abstract][Full Text] [Related]
9. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
12. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
Leese G; Jeffreys R; Vora J
Postgrad Med J; 1997 Aug; 73(862):507-8. PubMed ID: 9307745
[TBL] [Abstract][Full Text] [Related]
13. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas.
Renner U; Arzberger T; Pagotto U; Leimgruber S; Uhl E; Müller A; Lange M; Weindl A; Stalla GK
J Clin Endocrinol Metab; 1998 Apr; 83(4):1368-75. PubMed ID: 9543168
[TBL] [Abstract][Full Text] [Related]
15. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
[TBL] [Abstract][Full Text] [Related]
16. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
[TBL] [Abstract][Full Text] [Related]
17. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience.
Vargas-Ortega G; González-Virla B; Balcázar-Hernández L; Arreola-Rosales R; Benitez-Rodríguez FJ; López Félix B; Mercado M
Arch Endocrinol Metab; 2022 Sept 08; 66(4):506-511. PubMed ID: 35758837
[TBL] [Abstract][Full Text] [Related]
19. Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma.
Giusti M; Bocca L; Florio T; Foppiani L; Corsaro A; Auriati L; Spaziante R; Schettini G; Giordano G
J Endocrinol Invest; 2000; 23(7):463-6. PubMed ID: 11005271
[TBL] [Abstract][Full Text] [Related]
20. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas.
Taboada GF; Neto LV; Luque RM; Córdoba-Chacón J; de Oliveira Machado E; de Carvalho DP; Kineman RD; Gadelha MR
Neuroendocrinology; 2011; 93(1):40-7. PubMed ID: 21079388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
